Covered recipient · General Payments record
ASENA BAHCE-ALTUNTAS
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2018–2024
$2,373.20
- Reported across 112 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $340.58 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $151.10 | 4 |
| Amgen Inc. | $80.39 | 5 |
| Janssen Biotech, Inc. | $30.99 | 2 |
| Exact Sciences Corporation | $18.24 | 1 |
| SCILEX PHARMACEUTICALS INC. | $17.12 | 1 |
| ABBVIE INC. | $14.44 | 1 |
| Acerta Pharma LLC | $14.29 | 1 |
| Organon LLC | $14.01 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.44 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103263685 | CMS |
| Amgen Inc. | $14.40 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111522421 | CMS |
| Amgen Inc. | $16.04 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117195418 | CMS |
| Amgen Inc. | $16.79 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111522423 | CMS |
| Amgen Inc. | $16.83 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111522425 | CMS |
| Amgen Inc. | $16.33 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117195420 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.29 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105707994 | CMS |
| Exact Sciences Corporation | $18.24 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114582942 | CMS |
| GlaxoSmithKline, LLC. | $122.43 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116088881 | CMS |
| GlaxoSmithKline, LLC. | $5.82 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116312460 | CMS |
| GlaxoSmithKline, LLC. | $8.08 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116002511 | CMS |
| GlaxoSmithKline, LLC. | $14.77 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116447586 | CMS |
| Janssen Biotech, Inc. | $16.06 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078355045 | CMS |
| Janssen Biotech, Inc. | $14.93 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078355600 | CMS |
| Organon Llc | $14.01 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136225471 | CMS |
| SCILEX PHARMACEUTICALS INC. | $17.12 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136289289 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.